Fig. 4: Drug-target MR results assessing the impact of lipid-modulating and antihypertensive gene targets on mvAge.
Data presented are MR effect estimates (betas) for the IVW MR method (the primary MR method) and the corresponding 95% CIs aligned to proxy the pharmacological effect of modulated lipid levels (1 s.d. lower LDL-C (n = 440,546), 1 s.d. lower TG (n = 441,016), and 1 s.d. higher HDL-C (n = 403,943)) and SBP (n = 436,419) (antihypertensive gene targets (1 s.d. lower SBP) on mvAge (n = 1,958,774)). The vertical line in the center of the forest plots is 0, corresponding to no change in the IVW estimate of the drug targets on mvAge. Full results are presented in Supplementary Table 17. * indicates a P value surpassing the Bonferroni-adjusted P-value threshold = 0.002, corrected for the 25 antidiabetic, lipid-modulating and antihypertensive drug targets compared. P values are derived from two-sided Wald tests. Gene names for the nearest mapped genes are italicized. Lp(a), lipoprotein a.
